4.7 Article

Fe3O4-Au Core-Shell Nanoparticles as a Multimodal Platform for In Vivo Imaging and Focused Photothermal Therapy

Journal

PHARMACEUTICS
Volume 13, Issue 3, Pages -

Publisher

MDPI
DOI: 10.3390/pharmaceutics13030416

Keywords

imaging-guided therapy; multimodal imaging; contrast agent; MRI; CT

Funding

  1. Spanish Ministry of Economy, Industry and Competitiveness [CTQ2017-86655-R, BIO2017-84246-C2-1-R]
  2. Fondo Social de la DGA (grupos DGA)
  3. Regional Ministry of Health of Andalusia [OH-0026-2018]
  4. Associate Laboratory for Green Chemistry-LAQV - Portuguese national funds from FCT/MCTES [UIDB/04378/2020, UIDB/50006/2020]
  5. Applied Molecular Biosciences Unit - UCIBIOC - Portuguese national funds from FCT/MCTES [UIDB/04378/2020, UIDB/50006/2020]

Ask authors/readers for more resources

The study reported the synthesis of gold-coated iron oxide nanoparticles capped with polyvinylpyrrolidone, demonstrating their potential applications in multimodal imaging and photothermal therapy. Experimental results showed excellent efficiency in killing glioblastoma cells and reliable pharmacokinetics and biodistribution in animal models. Additionally, the study confirmed the limitations of intravenous administration for tumor targeting, suggesting intratumoral administration for therapeutic applications.
In this study, we report the synthesis of gold-coated iron oxide nanoparticles capped with polyvinylpyrrolidone (Fe@Au NPs). The as-synthesized nanoparticles (NPs) exhibited good stability in aqueous media and excellent features as contrast agents (CA) for both magnetic resonance imaging (MRI) and X-ray computed tomography (CT). Additionally, due to the presence of the local surface plasmon resonances of gold, the NPs showed exploitable light-to-heat conversion ability in the near-infrared (NIR) region, a key attribute for effective photothermal therapies (PTT). In vitro experiments revealed biocompatibility as well as excellent efficiency in killing glioblastoma cells via PTT. The in vivo nontoxicity of the NPs was demonstrated using zebrafish embryos as an intermediate step between cells and rodent models. To warrant that an effective therapeutic dose was achieved inside the tumor, both intratumoral and intravenous routes were screened in rodent models by MRI and CT. The pharmacokinetics and biodistribution confirmed the multimodal imaging CA capabilities of the Fe@AuNPs and revealed constraints of the intravenous route for tumor targeting, dictating intratumoral administration for therapeutic applications. Finally, Fe@Au NPs were successfully used for an in vivo proof of concept of imaging-guided focused PTT against glioblastoma multiforme in a mouse model.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available